Financial Risk Assessment And Countermeasures Of Y Pharmaceutical Company

The pharmaceutical industry is closely related to the national economy and people’s livelihood and is a industry that has attracted public attention.With the rapid development of science and technology,China’s pharmaceutical industry is also undergoing changes.At present,China’s pharmaceutical enterprises,compared with developed countries,have a slight lack of innovation capabilities,and to a certain extent are facing the impact of foreign pharmaceutical companies.In addition,the competition between domestic pharmaceutical companies has also intensified,which has led to a sharp increase in the probability of financial risks for Chinese pharmaceutical companies.Therefore,China’s pharmaceutical enterprises should fully recognize and guard against financial risk,and it is very important to establish a financial risk evaluation system that suits the enterprise itself.Taking Y Pharmaceutical Company as an example,this paper first expounds the theory of financial risk,and provides strong theoretical support for the following.Then,from the two aspects of the industry and the enterprise itself,through the financial statement data of the past three years,the existing financial risks are initially identified.Based on the above theoretical foundation and combining with the enterprise reality,the financial risk evaluation system for Y pharmaceutical companies is constructed from the financial and non-financial perspectives.Twelve financial indicators were selected from the four aspects of investment risk,financing risk,operational risk,and growth risk.The expert opinions of the company were combined.The weight of financial indicators was determined using the analytic hierarchy process,and the efficiency coefficient method was used to standardize the indicators and calculate the financial indicators.Risk score;Starting from the four non-financial dimensions of corporate governance,human resource status,market share,innovation and potential development ability,we obtained a risk rating of non-financial indicators by referring to company information and questionnaires,and the proportion of financial indicators was 80 %.Non-financial index ratio of 20 % calculated Y pharmaceutical company’s comprehensive financial risk score,determine the company’s financial risk degree,and from multiple angles to give corresponding preventive measures,cost control;optimize their own products,expand market share;optimize capital structure;improve asset utilization efficiency;improve the level of information technology,optimize human resources management.It is hoped that through this study,it can provide some references for the financial risk evaluation and prevention of pharmaceutical companies.